BioSight Ltd.

BioSight Ltd. is an Israeli biopharmaceutical company focused on developing innovative cancer therapeutics that enhance treatment efficacy while minimizing side effects through advanced drug delivery systems. Founded in 2000 and headquartered in Lod, Israel, BioSight Ltd. is engaged in the development of cancer therapies.

The company has secured a total of three deals, with its most recent funding round being a Series C completed on December 2, 2020, raising USD 27. 00 mn. This round was led by the Israel Biotech Fund and included investments from Arkin Holdings, BioTelemetry, Inc. , Migdal Insurance Company, Phoenix Insurance Company, and Primera Capital.

The firm was founded by a team with relevant experience in biopharmaceuticals, although specific details about the founder's history are not disclosed. BioSight Ltd. specializes in developing innovative cancer therapeutics, focusing on enhancing treatment outcomes for patients with various malignancies. The company is known for its proprietary drug delivery platform, which optimizes the therapeutic index of chemotherapeutic agents.

Its flagship product targets specific cancer types and aims to address unmet medical needs in oncology. BioSight serves oncologists, hospitals, and research institutions primarily in North America and Europe, catering to a diverse client base of healthcare providers and pharmaceutical partners. BioSight generates revenue through strategic partnerships and collaborations within the pharmaceutical industry. Its revenue model is based on licensing agreements and milestone payments linked to the progression of its therapeutic products through clinical development.

This includes negotiations with healthcare institutions and biopharmaceutical companies to establish terms that support the adoption of its solutions, with common structures involving upfront payments and royalties on sales, ensuring stable income as products move from research to market availability. BioSight Ltd. plans to leverage its recent Series C funding of USD 27. 00 mn, raised in December 2020, to further develop its pipeline of innovative therapeutics.

The company is focusing on launching new products aimed at specific oncology markets and enhancing its proprietary drug delivery mechanisms. Plans for geographic expansion include targeting additional regions in Europe and North America, with specific timelines for new market entries yet to be disclosed. The strategic funding will support clinical trial advancements and regulatory submissions necessary for product launches.